Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation
← catalyst calendarNCT06247280 · readout in 134 d
Sponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →. With The Korean Academy of Tuberculosis and Respiratory Diseases.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
2,001actual
Sites
39
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-24 | actual | When the study began enrolling |
| Primary completion | 2026-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NSCLC
Primary outcomes
what the primary-completion date above is the date OFClinical characteristics of NSCLC patients with EGFR mutation
measured 12months, 18months, 24months, 36months
Clinical outcome of NSCLS patients with EGFR mutation
measured 12months, 18months, 24months, 36months
PFS
measured 12months, 18months, 24months, 36months
DFS
measured 12months, 18months, 24months, 36months
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed